Pancreatic Cancer Research

Clinical trialNo phase (not a drug trial)Withdrawn

Personalized Management of Pancreatic Adenocarcinoma Using Patient-Derived Tumoroids

Establishing a Platform for Personalized Approach to the Management of Pancreatic Adenocarcinoma Using Patient-Derived Tumoroids

Outcome
Stopped earlystudy PI no longer at Institution (Other)
Phase
No phase (not a drug trial)
Status
Withdrawn
Study type
Interventional
Planned start
1 January 2022
Planned end
31 December 2023
Enrollment
0 participants
Sites
0
Primary outcomes
Rate of the successful establishment of pancreatic patient-derived tumoroids (PDT)
Sponsor type
Academic / other
Results posted
No
Last update
24 February 2022

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

This study is designed to prospectively investigate the feasibility of establishing patient-derived tumoroids (PDT) as a platform for a personalized approach for response prediction and guide optimal neoadjuvant and/or adjuvant approach. PDT will be investigated to determine drug sensitivity, predict the response to chemotherapy agents and radiation therapy, and validate this response in treated patients, and to establish the feasibility of PDT as a platform for a personalized approach to guide multimodality treatment.